Search

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

97.86 -1.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

98.13

Max

101.58

Belangrijke statistieken

By Trading Economics

Inkomsten

-49M

-105M

Verkoop

11M

71M

EPS

-0.73

Winstmarge

-147.27

Werknemers

414

EBITDA

6.2M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+45.2% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-245M

6.8B

Vorige openingsprijs

99.35

Vorige sluitingsprijs

97.86

Nieuwssentiment

By Acuity

87%

13%

310 / 339 Rangschikking in Healthcare

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 sep 2026, 20:07 UTC

Event
Correlated Moves
News

Rhythm Pharmaceuticals' IMCIVREE® received Health Canada approval for weight management in patients with acquired hypothalamic obesity, boosting shares higher during the session.

21 sep 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc is higher today, continuing an upward trend since Friday, despite mid-morning volatility and remaining below its 20-day moving average.

18 sep 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, settling near the lower end of their one-month range and significantly below the 20-day moving average.

17 sep 2026, 20:07 UTC

Correlated Moves

Rhythm Pharmaceuticals advances during Thursday's session, boosted by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16 sep 2026, 20:10 UTC

Rhythm Pharmaceuticals Inc is experiencing an upward movement during Wednesday's trading session, recovering from an early low with a peak return of 4.17%.

15 sep 2026, 20:01 UTC

News

Rhythm Pharmaceuticals shares are lower amid concerns from CEO insider selling and a drop in the NY Empire State Manufacturing Index for September.

14 sep 2026, 20:08 UTC

Rhythm Pharmaceuticals Inc. shares are lower today, continuing a decline since Friday's close, despite an earlier rebound from session lows.

11 sep 2026, 19:52 UTC

Rhythm Pharmaceuticals shares are higher during Friday's session, pulling back from earlier gains. No specific news was identified to explain the movement.

8 sep 2026, 20:08 UTC

Correlated Moves

RYTM trades lower as the biotech sector faces pressure.

2 sep 2026, 20:08 UTC

News

Rhythm Pharmaceuticals is higher today, supported by gains in the Biotechnology sector and CFO share transactions that reflect confidence in future performance.

1 sep 2026, 19:26 UTC

News

Rhythm Pharmaceuticals reported a net loss of -$33.26 million on revenue of $17.28 million. Shares are lower, continuing a trend of three consecutive sessions finishing down.

31 aug 2026, 23:46 UTC

Rhythm Pharmaceuticals Inc shares rose in after-market trading, reflecting a gradual increase from earlier lows, though still below the 20-day moving average.

28 aug 2026, 20:02 UTC

News

Rhythm Pharmaceuticals Inc shares are lower as Deutsche Bank initiates coverage with a Hold rating and a price target of $120.

26 aug 2026, 20:08 UTC

News

Rhythm Pharmaceuticals is trading lower, influenced by declines in the Biotechnology sector and a broader market downturn since Tuesday's close.

25 aug 2026, 21:02 UTC

Rhythm Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline, contrasting recent upward trends.

21 aug 2026, 19:36 UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

20 aug 2026, 20:02 UTC

Correlated Moves

Rhythm Pharmaceuticals is lower today, influenced by a significant decline in the Biotechnology sector and high trading volume. The stock has dropped sharply since Wednesday.

13 aug 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 aug 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 aug 2026, 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 aug 2026, 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 aug 2026, 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 aug 2026, 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 aug 2026, 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 aug 2026, 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 aug 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 jul 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 jul 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

45.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 143.5 USD  45.2%

Hoogste 160 USD

Laagste 120 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Sentiment

By Acuity

310 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.